Enveda, a biotechnology company using AI to translate nature into new medicines, is proud to announce testing of its lead asset, ENV-294, in a second indication: asthma. This novel therapeutic, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback